Apply Now

Opioid Use Disorder
Research Study

Opioid addiction is a serious condition, and while medications like buprenorphine help people recover, some still experience cravings and relapse. Researchers are looking for ways to improve treatment and support long-term recovery. This study is an opioid addiction study that is testing a GLP-1 agonist drug. It will examine whether adding a study medication called brenipatide to standard treatment can reduce cravings and help people stay on track with their recovery.

Apply Now

Fast Facts

Diagnosed with opioid use disorder

Started buprenorphine treatment between 2-12 months ago

Compensation
up to $8,000

Conducted in Baltimore, MD and Rockville, MD

Apply Now

Additional Information

This study is being conducted to better understand opioid use disorder and to explore ways to improve treatment outcomes, reduce cravings, and support long-term recovery. It is also testing a GLP-1 agonist to see whether this type of medication may help reduce opioid cravings and support recovery.

You may be eligible for this study if you meet the following criteria.

Inclusion Criteria:

  • Diagnosed with opioid use disorder (OUD)
  • Starting buprenorphine in the last year
  • Still struggling with opioids
  • Able to attend regular in-person clinic visits
  • Ages 18–75

Exclusion Criteria:

  • Major medical or psychiatric conditions that would interfere with participation
  • Use of certain restricted medications
  • Diagnosis of certain other substance use disorders (e.g., cocaine, methamphetamine, sedative, hallucinogen, or inhalant use disorders)

Overall Duration
This study lasts several months. It includes a screening period of about 4 weeks, followed by a treatment phase of about 6 months, and a longer follow-up period.

In-Clinic Activities
Participants will attend regular in-person visits at the clinic throughout the study. At these visits, they will:

  • Complete health check-ups, including vital signs and physical exams
  • Provide urine samples for drug screening
  • Answer questionnaires about cravings, mood, and overall health
  • Receive weekly study medication (a GLP-1 agonist injection or placebo injection)
  • Have blood drawn at certain visits
  • Check in with staff about how they are taking their medication

 

Participants will continue taking their prescribed buprenorphine during the study. Some visits may also take place through telehealth (video or phone check-ins). No video or audio recordings are required beyond standard telehealth communication.

At-Home Activities
At home, participants will:

  • Continue taking their prescribed buprenorphine as directed
  • Stay in contact with the study team between visits as needed
  • Report how they are feeling and any changes in cravings, mood, or health

Participants may receive compensation for completing study visits, which can add up to as much as $8,000 over the course of the study. Transportation support, such as rideshare (Uber/Lyft), may be provided to help participants get to and from clinic visits.

Participants will also receive regular health monitoring by study clinicians, free lab work and health assessments, support during the recovery process, and snacks during clinic visits.

There is no cost for you to participate in our research study.

Terms of Service

Privacy Policy

Tagged